United Therapeutics (UTHR) Capital Expenditures Growth (3y) (2012 - 2026)
United Therapeutics (UTHR) Capital Expenditures Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 28.56% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 279.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.58% |
| Dec 31, 2025 | -592.73% |
| Sep 30, 2025 | 166.14% |
| Jun 30, 2025 | -35.93% |
| Mar 31, 2025 | 77.03% |
| Dec 31, 2024 | 7.09% |
| Sep 30, 2024 | 17.71% |
| Jun 30, 2024 | 227.63% |
| Mar 31, 2024 | 66.64% |
| Dec 31, 2023 | -31.98% |
| Sep 30, 2023 | -24.08% |
| Jun 30, 2023 | 54.87% |
| Mar 31, 2023 | 12.28% |
| Dec 31, 2022 | 29.18% |
| Sep 30, 2022 | -32.07% |
| Jun 30, 2022 | 41.04% |
| Mar 31, 2022 | -18.68% |
| Dec 31, 2021 | 37.21% |
| Sep 30, 2021 | -25.88% |
| Jun 30, 2021 | 55.33% |